EPM
ALNY icon

Elm Partners Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Elm Partners Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$646K Buy
2,043
+35
+2% +$11.9K 0.03% 82
2025
Q4 		$798K Buy
+2,008
New +$889K 0.04% 79

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elm Partners Management's ALNY Position: Q1 2026 in Review

Elm Partners Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.7% in Q1 2026, buying an estimated $11.9K and bringing the position to 2,043 shares worth $646K. The position accounts for 0.03% of the portfolio, ranked #82.

Elm Partners Management first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $798K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Elm Partners Management held 2,043 shares of Alnylam Pharmaceuticals worth $646K as of Q1 2026.
  • Elm Partners Management bought 35 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $11.9K.
  • Alnylam Pharmaceuticals made up 0.03% of Elm Partners Management's portfolio in Q1 2026, its #82 holding.
  • Elm Partners Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Elm Partners Management's Alnylam Pharmaceuticals position peaked at $798K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Elm Partners Management's 13F filing for Q1 2026, filed 13 May 2026.